Ovagen is strictly for laboratory research and is commonly employed in the following investigational areas:

Hepatic Function and Liver Regeneration

Research models utilize Ovagen to evaluate its targeted efficacy in hepatic cellular systems. Investigations focus on the peptide’s ability to modulate transcriptional activity, evaluating changes in extracellular matrix organization, fibrotic-marker expression, and overall hepatocellular repair mechanisms under toxic stress.

Gastrointestinal Mucosal Stability

Experimental protocols employ this tripeptide to characterize its influence on the gastrointestinal tract. Studies assess its role in maintaining epithelial barrier integrity and regulating mucosal signaling pathways during simulated aging or stress events.

Enzymatic Inhibition and Molecular Biology

In biochemical research, short hydrophilic peptides like Ovagen (EDL) are used to study molecular interactions with specific viral targets. Researchers evaluate its capacity to interact with viral protease enzymes (such as HIV-1 protease) in vitro, using substrate-cleavage assays to define peptide-protease binding dynamics.

Pathway / Mechanistic Context

The primary mechanism of action for Ovagen in research settings involves its function as an epigenetic regulator of hepatic and gastrointestinal tissue, alongside its structural enzymatic interactions.

• Epigenetic Modulation: Enters the nucleus to normalize age-associated DNA methylation patterns and alter chromatin organization in hepatocytes and gastrointestinal cells.
• Cell Proliferation Regulation: Regulates markers associated with cellular aging, apoptosis, and proliferation (such as p53, p16, p21, and Ki-67) to support tissue functional recovery.
• Protease Inhibition: Binds specifically within the active sites of viral protease enzymes to inhibit enzymatic cleavage activity in purified in vitro assays.

Preclinical Research Summary

Published preclinical literature documents investigations of Ovagen across diverse experimental models focusing on hepatic metabolism, mucosal health, and enzymatic inhibition.

• In liver-derived cell studies, the EDL peptide was shown to normalize DNA methylation and modulate the transcription-factor accessibility associated with cellular aging.
• Animal models of toxic stress demonstrated that Ovagen supports functional recovery by regulating extracellular matrix components and reducing fibrotic markers in the liver.
• Biochemical studies using purified enzyme systems indicate that specific short hydrophilic peptides derived from analogous transframe sequences can inhibit the HIV-1 protease, providing mechanistic insight into enzymatic binding.

Form & Analytical Testing

• Solid-Phase Peptide Synthesis
• Lyophilization
• Identity Verification: Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the purity standard.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• J. M. Louis, F. Dyda, N. T. Nashed, A. R. Kimmel, and D. R. Davies, “Hydrophilic Peptides Derived from the Transframe Region of Gag-Pol Inhibit the HIV-1 Protease,” American Chemical Society (ACS), Feb. 1998. doi: 10.1021/bi972059x. https://doi.org/10.1021/bi972059x

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.